(8S,9R,10S,11R,13S,14S,17S)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (8S,9R,10S,11R,13S,14S,17S)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
• 英文别名: 9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
• 化学式: C₂₁H₂₉FO₅
• 分子量: 380.4
• InChiKey: AAXVEMMRQDVLJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID ACCUMULATION IN AND/ OR UNDER THE RETINA
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP2977084A1

  公开（公告）日：2016-01-27

  The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina.

  本发明提供了治疗视网膜内和/或视网膜下积液的方法和组合物。
• Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP2568986B1

  公开（公告）日：2016-01-13
• Oligomer-Corticosteroid Conjugates
  申请人：Zhang Wen

  公开号：US20100286107A1

  公开（公告）日：2010-11-11

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water soluble oligomer.
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASES
  申请人：Behar-Cohen Francine

  公开号：US20140024627A1

  公开（公告）日：2014-01-23

  The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease.
• OLIGOMER-CORTICOSTEROID CONJUGATES
  申请人：NAKTAR THERAPEUTICS

  公开号：US20140309398A1

  公开（公告）日：2014-10-16

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits different properties compared to the properties of the corticosteroid not attached to the water-soluble oligomer.